Avalo Therapeutics (AVTX) Gross Profit (2017 - 2024)

Avalo Therapeutics posted quarterly Gross Profit of -$465000.0 for Q3 2024, down 4127.27% year-on-year from $11546.3 in Q4 2023, and down 35.57% on a QoQ basis from -$343000.0 in Q2 2024.

Avalo Therapeutics (AVTX) has 8 years of Gross Profit data on file, last reported at -$465000.0 in Q3 2024.

  • For the quarter ending Q3 2024, Gross Profit fell 4127.27% year-over-year to -$465000.0; the trailing twelve-month figure through Sep 2024 stood at -$96000.0 (down 177.42% YoY), and the FY2023 full-year result was $640000.0, down 95.62% from the prior year.
  • Gross Profit for Q3 2024 stood at -$465000.0, down from -$343000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $14.4 million in Q3 2022 and bottomed at -$623000.0 in Q4 2020.
  • The 5-year median for Gross Profit is $276000.0 (2022), against an average of $1.1 million.
  • The widest annual swing landed in 2022, when Gross Profit surged 3162.67%; it then slumped 4127.27% in 2024.
  • A 5-year view of Gross Profit shows it stood at -$623000.0 in 2020, then surged by 67.09% to -$205000.0 in 2021, then jumped by 234.63% to $276000.0 in 2022, then surged by 186.96% to $792000.0 in 2023, then slumped by 158.71% to -$465000.0 in 2024.
  • The last three Gross Profit figures came in at -$465000.0 (Q3 2024), -$343000.0 (Q2 2024), and -$80000.0 (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Avalo Therapeutics 317.29 Mn 317.29 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 -465,000.00
Sep 30, 2024 -465,000.00
Jun 30, 2024 -343,000.00
Jun 30, 2024 -343,000.00
Mar 31, 2024 -80,000.00
Mar 31, 2024 -80,000.00
Dec 31, 2023 792,000.00
Dec 31, 2023 792,000.00
Sep 30, 2023 -11,000.00
Sep 30, 2023 -11,000.00
Jun 30, 2023 -65,000.00
Jun 30, 2023 -65,000.00
Mar 31, 2023 -76,000.00
Mar 31, 2023 -76,000.00
Dec 31, 2022 276,000.00
Dec 31, 2022 276,000.00
Sep 30, 2022 14.42 Mn
Sep 30, 2022 14.42 Mn
Jun 30, 2022 -534,000.00
Jun 30, 2022 -534,000.00
Mar 31, 2022 453,000.00
Mar 31, 2022 453,000.00
Dec 31, 2021 -205,000.00
Dec 31, 2021 -205,000.00
Sep 30, 2021 442,000.00
Sep 30, 2021 442,000.00
Jun 30, 2021 3.27 Mn
Jun 30, 2021 3.27 Mn
Mar 31, 2021 396,000.00
Mar 31, 2021 396,000.00
Dec 31, 2020 -623,000.00
Dec 31, 2020 -623,000.00
Sep 30, 2020 1.03 Mn
Sep 30, 2020 1.03 Mn
Jun 30, 2020 685,000.00
Jun 30, 2020 685,000.00
Mar 31, 2020 2.08 Mn
Mar 31, 2020 2.08 Mn
Dec 31, 2019 33,107.00
Dec 31, 2019 33,107.00
Sep 30, 2019 2.07 Mn
Sep 30, 2019 2.07 Mn
Jun 30, 2019 -104,735.00
Jun 30, 2019 -104,735.00
Mar 31, 2019 2.18 Mn
Mar 31, 2019 2.18 Mn
Dec 31, 2018 -1.46 Mn
Dec 31, 2018 -1.46 Mn
Sep 30, 2018 963,496.00
Sep 30, 2018 963,496.00
Jun 30, 2018 2.74 Mn
Jun 30, 2018 2.74 Mn
Mar 31, 2018 4.47 Mn
Mar 31, 2018 4.47 Mn
Dec 31, 2017 1.28 Mn
Dec 31, 2017 1.28 Mn
Sep 30, 2017 25.04 Mn
Sep 30, 2017 25.04 Mn
Jun 30, 2017 157,800.00
Jun 30, 2017 157,800.00
Mar 31, 2017 384,206.00
Mar 31, 2017 384,206.00